News | April 19, 2022
Akron Bio completes plasmid DNA manufacturing facility
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Subscribe To Our Newsletter & Stay Updated
